Preclinical Abuse Potential Assessment of Flibanserin: Effects on Intracranial Self-Stimulation in Female and Male Rats

The Journal of Sexual Medicine
Matthew F LazenkaS Stevens Negus

Abstract

Flibanserin is a serotonin receptor subtype 1A agonist and 2A antagonist that has been approved by the Food and Drug Administration for treating female sexual interest and arousal disorder. Little is known about the abuse potential of flibanserin. To examine abuse-related effects of flibanserin in rats using an intracranial self-stimulation (ICSS) procedure previously used to evaluate the abuse potential of other drugs. Adult female and male Sprague-Dawley rats with electrodes implanted in the medial forebrain bundle were trained to press a lever for electrical brain stimulation under a "frequency-rate" ICSS procedure. In this procedure, increasing frequencies of brain stimulation maintain increasing rates of responding. Drugs of abuse typically increase (or "facilitate") ICSS rates and produce leftward and upward shifts in ICSS frequency-rate curves, whereas drugs that lack abuse potential typically do not alter or only decrease ICSS rates. Initial studies determined the potency and time course of effects on ICSS produced by acute flibanserin administration (1.0, 3.2 and 10.0 mg/kg). Subsequent studies determined the effects of flibanserin (3.2-18 mg/kg) before and after a regimen of repeated flibanserin administration (5.6 mg...Continue Reading

References

Jan 1, 1991·Journal of Neural Transmission. General Section·A M MontgomeryL J Herberg
Jun 1, 1990·Journal of Clinical Psychopharmacology·R L Balster
Jan 1, 1986·Psychopharmacology·T H Hand, K B Franklin
Sep 1, 1995·Naunyn-Schmiedeberg's Archives of Pharmacology·F BorsiniA Donetti
Jan 1, 1996·Annual Review of Neuroscience·R A Wise
Feb 6, 1998·Psychopharmacology·F BorsiniL Seiden
Sep 24, 1999·Pharmacology, Biochemistry, and Behavior·F BorsiniN Pitsikas
Jan 5, 2002·European Journal of Pharmacology·F Borsini, R Cesana
Mar 22, 2002·Frontiers in Neuroendocrinology·Cynthia L BetheaJohn M Streicher
Dec 14, 2004·Journal of Neuroscience Methods·L BertP Lestage
Dec 25, 2004·Endocrinology·Jill B BeckerElizabeth Young
Jun 24, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Faïza BenaliouadPierre-Paul Rompré
Mar 8, 2007·Birth Defects Research. Part B, Developmental and Reproductive Toxicology·Jerome M GoldmanRalph L Cooper
Nov 17, 2007·Nature Protocols·William A Carlezon, Elena H Chartoff
May 16, 2009·Drug and Alcohol Dependence·Lawrence P Carter, Roland R Griffiths
Jan 14, 2012·The Journal of Sexual Medicine·John ThorpUNKNOWN DAISY trial investigators
Oct 13, 2012·The Journal of Sexual Medicine·Christopher JayneUNKNOWN SUNFLOWER study investigators
Aug 16, 2013·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Kevin S MurnaneLeonard L Howell
Nov 28, 2013·Menopause : the Journal of the North American Menopause Society·James A SimonMichael Sand
Jun 29, 2014·Pharmacological Reviews·S Stevens Negus, Laurence L Miller
Apr 7, 2015·Experimental and Clinical Psychopharmacology·Matthew F LazenkaS Stevens Negus
Sep 29, 2015·Drugs·Emma D Deeks

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.